Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. Kenneth Cooke

Kenneth R Cooke, M.D.

Director, Pediatic Blood and Marrow Transplantation Program
Professor of Oncology

Male

Appointment Phone

443-287-6997

Main Location

The Johns Hopkins Hospital

Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Director, Pediatic Blood and Marrow Transplantation Program
  • Professor of Oncology

Centers & Institutes

Departments

  • Oncology - Pediatric Oncology

Locations

The Johns Hopkins Hospital

Appointment Phone: 443-287-6997

600 N. Wolfe Street
Charlotte R. Bloomberg Childrens Center
Baltimore, MD 21287 map
Phone: 443-287-4959

Expertise

Bone Marrow Failure, Bone Marrow Transplant, Bone Marrow Transplant, Haploidentical, Medical Oncology, Pediatric Cancer, Pediatric Oncology

Research Interests

Bone Marrow Transplant, Pediatric Oncology, Pediatric Bone Marrow Transplant

Biography

Dr. Cooke is Director of the Kimmel Cancer Center’s Pediatric Bone Marrow Transplantation Program. Prior to his appointment at Johns Hopkins, Dr. Cooke headed the Pediatric Blood and Marrow Transplantation Program at Rainbow Babies and Children’s Hospital, and University Hospitals Case Medical Center, in Cleveland, Ohio. He also co-directed the Hematologic Disorders Program of the Case Comprehensive Cancer Center at Case Western Reserve University.

A nationally recognized transplantation immunology expert, Dr. Cooke’s work focuses primarily on new strategies to prevent and treat graft-vs-host disease and lung complications following blood and bone marrow transplantation. His research efforts have been recognized by the Leukemia and Lymphoma Society and the American Society of Clinical Investigation. In addition, Dr. Cooke is interested in the delivery of cancer care to adolescent and young adult populations.

 

...read more

    Additional Information

  • Education +

    Degrees

    • Rutgers-Robert Wood Johnson Medical School / MD (1990)

    Residencies

    • Children's Hospital of Philadelpha / Pediatrics (1993)

    Fellowships

    • Dana-Farber Cancer Institute (1996)
  • Research & Publications +

    Clinical Trials:

    Bone Marrow Transplant


    Clinical Trial Keywords: Bone Marrow Transplant

    Selected Publications

    1. Pareek TK, Lam E, Zheng X, Askew D, Kulkarni AB, Chance MR, Huang AY, Cooke KR, Letterio JJ. Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelisis. J Exp Med 2010; 207: 2507-19. PMCID 2964575.

    2. Paczesny P, Diaz-Ricart M, Carreras E, Cooke KR. Translational research efforts in biomarkers and the biology of early transplant-related complications. Biol Blood Marrow Transplant 2011; 17: S101-8.

    3. Panoskaltsis-Mortari A, Griese M, Madtes DK, Belperio JA, Haddad IY, Folz RJ, Cooke KR. An Official American Thoracic Society Research Statement: Noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med 2011; 183: 1262-79. PMCID 3266140.

    4. Nieder ML, McDonald GB, Kida A, Hingorani S, Armenian SH, Cooke KR, Pulsipher MA, Baker KS. NCI, NHLBI First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Long Term Organ Damage and Dysfunction Following Pediatric Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2011; 17: 1573-84. PMCID 3215762.

    5. Pulsipher MA, Skinner R, McDonald, GB, Hingorani S, Armenian SH, Cooke KR, Gracia C, Petryk A, Bhatia S, Bunin N, Nieder ML, Dvorak CC1, Sung L, Sanders JE, Kurtzberg, J, Baker KS. NCI, HLBI/PBMTC First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: The Need for Pediatric Specific Long Term Follow-up Guidelines. Biol Blood Marrow Transplant 2012; 18: 334-47. PMCID 3281504.

    6. Koenig GC, Rowe RG, Day SM, Sabeh F, Atkinson JJ, Cooke, KR, Weiss SJ. MT1-MMP-Dependent Remodeling of Cardiac Extracellular Matrix Structure and Function Following Myocardial Infarction. Am J Path 2012; 180: 1863-78. PMCID 3349831.

    7. Schlatzer DM, Dazard JE, Ewing RM, Ilchenko S, Rana G, Yanik G, Chance MR, Cooke KR. Human biomarker discovery and predictive models for disease progression for idiopathic pneumonia syndrome following allogeneic stem cell transplantation. Molec Cellular Proteomics 2012; 11: M111.015479. PMCID 3433920.

    8. Yanik GA, Mineishi S, Levine JE, Kitko CL, White ES, Vander Lugt MT, Harris AC, Braun T, Cooke KR. Soluble Tumor Necrosis Factor Receptor: Enbrel (etanercept) for sub-acute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1044-54.

    9. Kaur P, Schlatzer D, Cooke KR, Chance MR. Pairwise Protein Expression Classifier Candidate Biomarker Discovery for Early Detection of Human Disease Prognosis. BMC Bioinformantics 2012; 13: 191. PMCID 3468399.

    10. Choi SW, Stiff P, Cooke KR, Ferrara JLM, Braun T, Kitko C, Reddy R, Yanik G, Mineishi S, Paczesny S, Hanauer D, Pawarode A, Peres E, Rodriguez T, Smith S, Levine JE. TNF-inhibition with etanercept for graft versus host disease prevention in high risk HCT:Lower TNFR1 levels correlate with better outcomes. Biol Blood Marrow Transplant 2012; 18: 1525-32. PMCID 3443302.

    11. Akpek G, Pasquini MC, Logan B, Agovi MA, Lazarus H, Marks DI, Bornhaeüser M, Ringdén O, Maziarz RT, Gupta V, Popat U, Maharaj D, Bolwell BJ, Rizzo JD, Ballen KK, Cooke KR, McCarthy PL, Ho VT. Effects of splenectomy, splenic irradiation, and splenomegaly on early outcomes after hematopoietic cell transplantation. Bone Marrow Transplant 2012; 46: 825-31. PMCID 3606905.

    12. Huang AY, Haining WN, Barkauskas DS, Myers JT, Petrosiute A, Garrett AP, Singh K, Cooke KR, Kean LS, Viewing transplantation immunology through today’s lens: new models, new imaging, and new insights. Biol Blood Marrow Transplant 2013; 19(1 Suppl): S44-51.

    13. Bredeson C, LeRademacher J, Kato K, DiPersio JF, Agura E, Devine SM, Appelbaum FR, Tomblyn MR, Laport GG, Zhu X, McCarthy PL, Ho VT, Cooke KR, Armstrong E, Smith A,. Rizzo JD, Burkart JM and Pasquini MC. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood 2013; 122: 3871-8. PMCID 3854109

    14. Cooke KR. A "window of opportunity" for patients with late-onset pulmonary dysfunction after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014; 20(3): 291-2.

    15. Bhaskaran S, Abu-Arja RF, Abusin G, Cabral L, Nagle K, Ahuja S, Edler R, Cooke KR, Lazarus HM. Recombinant human keratinocyte growth factor: successful treatment of severe, refractory hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2014; 43(12): 1550-1.

    16. Aplenc R, Zhang MJ, Sung L, Zhu X, Ho V, Cooke KR, Dvorak C, Hale G, Isola L, Lazarus H, McCarthy P, Olson R, Pulsipher M, Pasquini M, Bunin N, on behalf of the Regimen-Related Toxicity Writing Committee. Center for International Blood and Marrow Transplant Research. Effect of Body Mass in Children with Hematologic Malignancies undergoing Allogeneic Bone Marrow Transplantation. Blood 2014; 123(22):3504-11. PMCID 4041168

    17. Abu-Arja RF, Gonzalez BE, Jacobs MR, Cabral L, Egler R, Auletta J, Arnold J, Cooke KR. Disseminated Bacillus Calmette-Guerin (BCG) infection following allogeneic hematopoietic stem cell transplant in a patient with Bare Lymphocyte Syndrome type II. Transpl Infect Dis 2014; 16(5): 830-7.

    18. Yanik GA, Horowitz MH, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ Carter SL, Wu J, Wingard JR, Difronzo NL, Ferrara JLM, Giralt S, Madtes DK, White, ES, Cooke KR. A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome Following Allogeneic Stem Cell Transplantation. A Blood and Marrow Transplant Clinical Trials Network Protocol. Biol Blood and Marrow Transpl 2014; 20(6):858-64. PMCID 4128626

    19. Paczesny S, Duncan C, Jacobsohn D, Krance R, Leung K, Carpenter P, Bollard C, Renbarger J, Cooke KR. Opportunities and challenges of proteomics in pediatric patients: circulating biomarkers after hematopoietic stem cell transplantation as a successful example. Proteomics Clin Appl. 2014; 8(11-12):837-50. PMCID4361082

    20. Klein O, Cooke KR. Idiopathic Pneumonia Syndrome Following Hematopoietic Stem Cell Transplantation. J Ped Intensive Care 2014; 3: 147-157.

    21. Yanik GA, Grupp SA, Pulsipher MA, Levine JE, Schulz KR, Wall DA, Langholz B, Dvorak CC, Alangaden K, Goyal RK, White ES, Collura JM, Skeens MA, Eid S, Pierce EM, Cooke KR, TNF-receptor inhibitor therapy for the treatment of children with idiopathic puenmonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children’s Oncology Group Study (ASCT0521). Biol Blood Marrow Transplant 2015; 21(1): 67-73. PMCID 4286345.

    22. Auletta JJ, Eid S, Metheny L, Keller MD, Guardia-Wolff R,, Liu C, Wang F, Lee Z, Solchaga LA, Cooke KR. Human bone marrow-derived mesenchymal stem cells attenuate graft-versus-host disease and maintain graft-versus-leukemia in an experimental murine model of allogeneic bone marrow transplantation., Stem Cells 2015; 33(2): 601-14. PMCID 4304927

    23. Varelias A, Gartlan KH, Kreijveld E, Olver SD, Lor M, Kuns RD, Lineburg KE, Teal BE, Raffelt NC, Cheong M, Alexander KA, Koyama M, Markey KA, Sturgeon E, Leach J, Reddy P, Kennedy G, Yanik G, Blazar BR, Tey SK, Clouston A, MacDonald KPA, Cooke KR, Hill GR. A Critical contribution of Lung parenchyma–derived IL-6 t acute lung injury after allogeneic stem cell transplantation, Blood 2015; 125(15): 2435-44.

    24. Chen Y, Lane AA, Logan B, Maziarz R, Zhu X, Lazarus H, Ahmed I, Bredeson C, Akpek G, Olson R, Hsu JW, Saber W, Hale G, Smith F, Aljurf M, Artz A, Cooke KR, Vincent Ho, Philip McCarthy, Marcelo C. Pasquini on behalf of the CIBMTR Regimen Related Toxicity Committee. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21(6): 1046.53. PMCID 4426014

    25. Paczesny S, Hakim FT, Pidala J, Cooke KR, Lathrop J, Griffith LM, Hansen J, Jagasia M, Miklos D, Pavletic S, Parkman R, Russek-Cohen E, Flowers MED, Lee S, Martin P, Vogelsang G, Walton M, Schultz KR. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant 2015; 21(5): 780.92. PMCID 4408233

  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
Is This You? Edit Profile
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.